用于筛选荧光引导手术探针的多光谱三维活体类器官成像平台。

IF 9 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

EMBO Molecular Medicine Pub Date : 2024-07-01 Epub Date: 2024-06-03 DOI:10.1038/s44321-024-00084-4

Bernadette Jeremiasse, Ravian L van Ineveld, Veerle Bok, Michiel Kleinnijenhuis, Sam de Blank, Maria Alieva, Hannah R Johnson, Esmée J van Vliet, Amber L Zeeman, Lianne M Wellens, Gerard Llibre-Palomar, Mario Barrera Román, Alessia Di Maggio, Johanna F Dekkers, Sabrina Oliveira, Alexander L Vahrmeijer, Jan J Molenaar, Marc Hwa Wijnen, Alida Fw van der Steeg, Ellen J Wehrens, Anne C Rios

{"title":"用于筛选荧光引导手术探针的多光谱三维活体类器官成像平台。","authors":"Bernadette Jeremiasse, Ravian L van Ineveld, Veerle Bok, Michiel Kleinnijenhuis, Sam de Blank, Maria Alieva, Hannah R Johnson, Esmée J van Vliet, Amber L Zeeman, Lianne M Wellens, Gerard Llibre-Palomar, Mario Barrera Román, Alessia Di Maggio, Johanna F Dekkers, Sabrina Oliveira, Alexander L Vahrmeijer, Jan J Molenaar, Marc Hwa Wijnen, Alida Fw van der Steeg, Ellen J Wehrens, Anne C Rios","doi":"10.1038/s44321-024-00084-4","DOIUrl":null,"url":null,"abstract":"Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.","PeriodicalId":11597,"journal":{"name":"EMBO Molecular Medicine","volume":" ","pages":"1495-1514"},"PeriodicalIF":9.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251264/pdf/","citationCount":"0","resultStr":"{\"title\":\"A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery.\",\"authors\":\"Bernadette Jeremiasse, Ravian L van Ineveld, Veerle Bok, Michiel Kleinnijenhuis, Sam de Blank, Maria Alieva, Hannah R Johnson, Esmée J van Vliet, Amber L Zeeman, Lianne M Wellens, Gerard Llibre-Palomar, Mario Barrera Román, Alessia Di Maggio, Johanna F Dekkers, Sabrina Oliveira, Alexander L Vahrmeijer, Jan J Molenaar, Marc Hwa Wijnen, Alida Fw van der Steeg, Ellen J Wehrens, Anne C Rios\",\"doi\":\"10.1038/s44321-024-00084-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.\",\"PeriodicalId\":11597,\"journal\":{\"name\":\"EMBO Molecular Medicine\",\"volume\":\" \",\"pages\":\"1495-1514\"},\"PeriodicalIF\":9.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251264/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMBO Molecular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s44321-024-00084-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMBO Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s44321-024-00084-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

实现肿瘤的完全切除具有挑战性，而使用分子靶向探针进行实时荧光引导手术则可改善这一问题。然而，探针的临床前鉴定和验证是一个漫长的过程，传统上是在动物模型中进行的，肿瘤间和肿瘤内靶点表达的异质性进一步阻碍了这一过程。为了在患者范围内筛选多种探针，我们开发了一种多光谱实时三维成像平台，该平台采用类器官技术，能有效模拟患者肿瘤的异质性，更重要的是，还能与健康人体组织结合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery.

Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

EMBO Molecular Medicine 医学-医学：研究与实验

CiteScore

17.70

自引率

0.90%

发文量

105

审稿时长

4-8 weeks

期刊介绍： EMBO Molecular Medicine is an open access journal in the field of experimental medicine, dedicated to science at the interface between clinical research and basic life sciences. In addition to human data, we welcome original studies performed in cells and/or animals provided they demonstrate human disease relevance. To enhance and better specify our commitment to precision medicine, we have expanded the scope of EMM and call for contributions in the following fields: Environmental health and medicine, in particular studies in the field of environmental medicine in its functional and mechanistic aspects (exposome studies, toxicology, biomarkers, modeling, and intervention). Clinical studies and case reports - Human clinical studies providing decisive clues how to control a given disease (epidemiological, pathophysiological, therapeutic, and vaccine studies). Case reports supporting hypothesis-driven research on the disease. Biomedical technologies - Studies that present innovative materials, tools, devices, and technologies with direct translational potential and applicability (imaging technologies, drug delivery systems, tissue engineering, and AI)